Tenaya Therapeutics picks up $106m Series C

Tenaya Therapeutics, a biotechnology company focused on treating the cause of heart disease, has secured $106 million in Series C funding.

Tenaya Therapeutics, a biotechnology company focused on treating the cause of heart disease, has secured $106 million in Series C funding. The investors include RTW Investments, LP, RA Capital Management, Fidelity Management & Research Company, T. Rowe Price Associates, Inc, The Column Group, Casdin Capital and GV.

Source: Press Release